RA Capital

Synolo Therapeutics is advancing a new class of therapeutics for cancer. Launched by RA Ventures and leveraging a proprietary discovery platform, we are rapidly building a pipeline of differentiated conditionally-active immunotherapies which promise to be highly effective and safer than the current standard of care. RA Ventures is the venture-focused division of RA Capital Management.